Breaking News

Cambrex Advances U.S. and European Expansions

Charles City expansion will add a new API plant with 140,000 liters of capacity and $30M expansion in Milan will add new analytical development and process R&D capabilities.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Cambrex

Cambrex, a global CDMO, completed the initial engineering studies for its new, large-scale active pharmaceutical ingredient (API) manufacturing plant in Charles City, Iowa. This milestone is part of the company’s previously announced $120 million investment in expanding its U.S. API manufacturing capabilities. Groundbreaking for the new facility is scheduled to take place in late 2026. The Charles City expansion will add a new plant with 140,000 liters of capacity, including large-scale...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters